All In Biotech

Drug Trial Radar · NCT06137768

A Trial of HRS-5965 Tablets in Primary IgA Nephropathy

A Trial to Evaluate the Efficacy and Safety of HRS-5965 Tablets in Primary IgA Nephropathy

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

123

Actual

Start

Dec 19, 2023

Primary completion

Oct 17, 2025

Study completion Oct 17, 2025

Sponsor

Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, and safety of HRS-5965 tablets for primary IgA nephropathy. To explore the effective dosage of HRS-5965 tablets for primary IgA nephropathy.

Conditions

  • Primary IgA Nephropathy

Interventions

  • HRS-5965Drug

    HRS-5965

  • PlaceboDrug

    Placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of 24-hour Urinary protein to creatinine ratio (UPCR) to baselineTime frame: Baseline and Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.